Elevance Health (ELV) October 485 straddle priced into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Elevance (ELV) PT Lowered to $478 at RBC Capital
October 18, 2024 7:04 AM EDTRBC Capital analyst Ben Hendrix lowered the price target on Elevance (NYSE: ELV) to $478.00 (from $585.00) while maintaining a Outperform rating.
The analyst comments "ELV shares traded off today as management lowered its 2024 EPS guidance and guided to mid-single-digit EPS growth in 2025, down from... More
